• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Novo Nordisk A/S Common Stock (NY:NVO)

    38.50 UNCHANGED
    Streaming Delayed Price Updated: 7:00 PM EST, Mar 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 755,218
    Open 38.50
    Bid (Size) 38.50 (600)
    Ask (Size) 38.52 (300)
    Prev. Close 38.50
    Today's Range 38.50 - 38.50
    52wk Range 35.85 - 91.90
    Shares Outstanding N/A
    Dividend Yield 3.03%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    The Compounding Cliff: Hims & Hers Faces Reckoning as FDA and Big Pharma Close GLP-1 Loopholes
    NEW YORK — The era of easy access to compounded weight-loss "knockoffs" is rapidly drawing to a close, leaving the telehealth industry’s once-shining star, Hims & Hers Health, Inc. (NYSE: HIMS), in a... 
    Via MarketMinute
    Topics Economy Intellectual Property Lawsuit
    News headline image
    Novo Nordisk’s Brief Rebound Fizzles: Apple-Style Justin Long Ozempic Ad Draws FDA Warning Again ↗
    The notice comes weeks after a similar warning over Wegovy advertising, as the FDA ramps up scrutiny of marketing tied to GLP-1 drugs. 
    Via Stocktwits

    Performance

    YTD
    -26.5%
    -26.5%
    1 Month
    -34.7%
    -34.7%
    3 Month
    -19.1%
    -19.1%
    6 Month
    -32.1%
    -32.1%
    1 Year
    -56.0%
    -56.0%

    More News

    Read More
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Unexpected Stock Picks and Looking to the Future ↗
    Via The Motley Fool
    News headline image
    Why I'm Not Worried About Novo Nordisk Stock ↗
    Via The Motley Fool
    Topics Intellectual Property
    MarketBeat Week in Review – 02/23 - 02/27 ↗
    Via MarketBeat
    News headline image
    The Great Divergence: AI Supremacy Masks a Hidden Bear Market in Healthcare and Industrials
    Via MarketMinute
    Topics Artificial Intelligence Bonds Economy
    News headline image
    The Lilly Era: How Eli Lilly Transformed into a Trillion-Dollar Healthcare Titan
    Via MarketMinute
    Topics Artificial Intelligence ETFs
    News headline image
    The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026
    Via Finterra
    Topics Economy Intellectual Property
    News headline image
    Got $5,000? Hims & Hers Could Be a Direct‑to‑Consumer Health Moonshot in the Making ↗
    Via The Motley Fool
    News headline image
    Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play ↗
    Via The Motley Fool
    News headline image
    Why Shares of Novo Nordisk Stock Sank (Again) This Week ↗
    Via The Motley Fool
    News headline image
    Viking Therapeutics: The High-Stakes Weight Loss Contender ↗
    Via MarketBeat
    News headline image
    The Darwinian Transition: AI Monetization and Metabolic Mastery Define the Market’s New Frontier
    Via MarketMinute
    Topics Artificial Intelligence Economy
    News headline image
    Hims & Hers at the Crossroads: Navigating the ‘Regulatory Winter’ of 2026
    Via Finterra
    Topics Economy Initial Public Offering Intellectual Property
    News headline image
    Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore ↗
    Via The Motley Fool
    News headline image
    Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies ↗
    Via The Motley Fool
    Topics Stocks
    News headline image
    Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. ↗
    Via The Motley Fool
    News headline image
    1 Reason Why I'd Hold This Weight‑Loss Drug Leader Through Any Market Crash ↗
    Via The Motley Fool
    Topics Economy
    News headline image
    NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes ↗
    Via Stocktwits
    News headline image
    Novo Nordisk To Slash GLP-1 Drug Prices By Up To 50% In US Starting 2027 ↗
    Via Benzinga
    News headline image
    Could Novo Nordisk Help Turn $100,000 Into $1 Million in the GLP‑1 Gold Rush? ↗
    Via The Motley Fool
    News headline image
    Why Eli Lilly Stock Slumped Today ↗
    Via The Motley Fool

    Frequently Asked Questions

    Is Novo Nordisk A/S Common Stock publicly traded?
    Yes, Novo Nordisk A/S Common Stock is publicly traded.
    What exchange does Novo Nordisk A/S Common Stock trade on?
    Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
    What is the ticker symbol for Novo Nordisk A/S Common Stock?
    The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
    What is the current price of Novo Nordisk A/S Common Stock?
    The current price of Novo Nordisk A/S Common Stock is 38.50
    When was Novo Nordisk A/S Common Stock last traded?
    The last trade of Novo Nordisk A/S Common Stock was at 03/04/26 07:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.